RadNet (RDNT) shares surged 5.08% intraday on Wednesday, driven by Barclays' bullish stance on the medical imaging company.
Barclays analyst Andrew Mok CFA maintained a Buy rating on RadNet and set a price target of $74.00. This positive outlook from the analyst appears to be fueling the stock's rally.
RadNet has been viewed favorably by analysts due to its strong growth prospects and leadership position in the outpatient imaging services market. The company is expected to benefit from increasing demand for diagnostic imaging procedures as the population ages.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.